Home / Healthcare / Pharmaceutical / Middle East & Africa Botulinum Toxin Market
Middle East & Africa Botulinum Toxin Market Size, Share & Industry Analysis, By Application (Therapeutics {Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Blepharospasm, and Others}, and Aesthetics {Forehead Wrinkles, Glabellar Lines, Crow's Feet, and Others}), By Type (Botulinum Toxin Type A and Botulinum Toxin Type B), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2023-2030
Report Format: PDF | Published Date: May, 2023 | Report ID: FBI107507 | Status : PublishedMiddle East & Africa is the fifth largest region in the global botulinum toxin market. It is projected to grow at a CAGR of 2.6% during the forecast period. The global market for botulinum toxin is projected to grow from USD 7.23 billion in 2022 to USD 10.62 billion by 2030.
The demand for minimally non-invasive procedures such as neurotoxins, under-eye and jawline fillers are increasing due to the changing beauty standards. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS), 485,875 nonsurgical cosmetic procedures were performed in Turkey in 2021, of which 229,346 were botulinum toxin procedures. Numerous key players are entering into strategic partnerships and launching these products to secure a foothold in the Middle Eastern & African markets. In addition, the surge in awareness due to advertisements on social media platforms is expected to expand the market growth.
Our report on the Middle East & Africa botulinum toxin market covers the following countries/regions –GCC, South Africa and the Rest of Middle East & Africa.
LATEST TRENDS
Surge in Adoption of These Products among the Male Demographic Augments Market Growth
One of the key market trends is that the male demographic groups have shown increased inclination or demand for minimally invasive procedures or non-invasive procedures. The rising adoption of these aesthetic procedures to enhance their appearances is contributing to the market expansion during 2023-2030. According to an article published by Al Arabiya Network in 2021, clinics in Dubai reported a surge in neurotoxin and dermal filler procedures in men. A huge number of male patients also undergo cosmetic procedures with a desire to be more competitive and youthful in the workforce. Also, the growing adoption of cosmetic surgery and increased awareness of the safety and efficacy of the products are contributing to market growth during the forecast period.
DRIVING FACTORS
Increasing Research Activities to Prove the Efficacy of Procedures to Propel the Market Expansion
Ongoing research activities to evaluate the efficacy and safety of these procedures has been witnessed in the Middle East & African market. Multiple companies and organizations are emphasizing on various studies to increase product adoption in the market.
For instance, according to a study published in Neuroscience and Medicine in February 2022, a prospective study was conducted in Kuwait to understand patient satisfaction when administered botulinum toxin type A for different neurological disorders. The study concluded that the satisfaction with botulinum toxin type A therapy for different neurological disorders was overall good. Such positive results of studies favor more product adoption among the population.
Similarly, market players are focusing on approvals for various indications such as forehead lines, cervical dystonia, chronic migraine, tremors, etc. Such scenarios have augmented the market growth.
RESTRAINING FACTORS
Several Side Effects and High Costs Associated with Cosmetic Procedures to Deter the Market Growth
In spite of the robust demand for botulinum toxin, the high cost of such procedures affects product adoption in the market. For instance, according to AEDIT, LLC. article published in 2021, the cost for a Botox procedure ranges from USD 125.0 to USD 500.0 in the United Arab Emirates (UAE). Furthermore, several side effects associated with cosmetic procedures also adversely affects the market growth.
KEY INDUSTRY PLAYERS
Regarding the competitive analysis, AbbVie Inc. accounted for the largest share of the market in 2022 owing to an expanded product portfolio and strategic initiatives. AbbVie Inc. has a substantial presence in seven countries of Middle East & Africa which provides easy accessibility of their products to patients. Such factor contributes to the growth of the company in this region. Companies such as Ipsen Pharma and Merz Pharma hold substantial part in the Middle East & Africa botulinum market share. A strong emphasis on innovative product launches and a distribution network has helped the company maintain a suitable market position. Additionally, some other major players, HUGEL, Inc., GALDERMA, and others, are extensively engaged in a strategic initiative to gain a strong Middle East and Africa botulinum toxin market share in the near future.
LIST OF KEY COMPANIES PROFILED:
- AbbVie Inc. (U.S.)
- Ipsen Pharma (France)
- Merz Pharma (Germany)
- Medytox (South Korea)
- GALDERMA (Switzerland)
- HUGEL, Inc. (Republic of Korea)
- Evolus, Inc. (U.S.)
- Revance Therapeutics, Inc. (U.S.)
- Supernus Pharmaceuticals, Inc. (U.S.)
KEY INDUSTRY DEVELOPMENTS:
- January 2023: Medytox built a manufacturing facility for botulinum toxin products in the United Arab Emirates (UAE) to secure its foothold in the Middle Eastern market.
- February 2022: Merz Therapeutics expanded its strategic partnership with Vensica Therapeutics by investing USD 3.0 million in the Israel-based start-up. The investment follows the license and collaboration agreement between the two companies to utilize Merz’s botulinum toxin type A (Xeomin) for the innovative ultrasound-assisted delivery catheter by Vensica.
- August 2021: Mubadala Investment Company joined a group of Asian companies intending to acquire nearly half of HUGEL, Inc. from Bain Capital.
REPORT COVERAGE
The report on the Middle East & Africa’s market provides a detailed analysis. It includes key aspects such as market dynamics, an overview of the number of procedures by key countries, key industry developments pricing data, the regulatory and reimbursement scenario, pipeline analysis, competitive landscape, and COVID-19's impact on the market.
Report Scope & Segmentation
ATTRIBUTE | DETAILS |
Study Period | 2019-2030 |
Base Year | 2022 |
Estimated Year | 2023 |
Forecast Period | 2023-2030 |
Historical Period | 2019-2021 |
Growth Rate | CAGR of 2.6% from 2023 to 2030 |
Unit | Value (USD billion) |
Segmentation | Application; Type; End User; and Country/ Sub-Region |
By Application |
|
By Type |
|
By End User |
|
By Country/ Sub-Region |
|
Frequently Asked Questions
At what CAGR is the market projected to grow during the forecast period?
The Middle East & Africa botulinum toxin market is expected to gain a CAGR of 2.6% during the forecast period.
What are the key contributing factors to the market growth?
Rising demand for aesthetics procedures amongst all demographics and strong strategic initiatives by key market players contributes to the market growth.
What are the key players operating in the Middle East & Africa market?
Market players such as AbbVie Inc., Galderma, and Merz Pharma operate in the market.
Which country holds the topmost position in the market?
GCC holds the topmost position in the market.
- Middle East
- 2022
- 2019-2021
- 100